metricas
covid
Buscar en
Vacunas (English Edition)
Toda la web
Inicio Vacunas (English Edition) Comparison of clinical, radiological and laboratory findings in discharged and d...
Journal Information
Vol. 23. Issue S2.
COVID 19 & vaccines: Development and practice
Pages S36-S43 (September - December 2022)
Share
Share
Download PDF
More article options
Visits
23
Vol. 23. Issue S2.
COVID 19 & vaccines: Development and practice
Pages S36-S43 (September - December 2022)
Original
Comparison of clinical, radiological and laboratory findings in discharged and dead patients with COVID-19
Comparación de los hallazgos clínicos, radiológicos y de laboratorio en pacientes dados de alta y fallecidos con COVID-19
Visits
23
Mahbobe Jafaria, Maryam Akbaria, Maryam Navidkiaa, Shirin Dashtbinb, Seyede Faezeh Mousavia, Mohsen Heidaryc,d,
Corresponding author
mohsenheidary40@gmail.com

Corresponding authors.
, Saeed Khoshnoode,
Corresponding author
Saeed.Khoshnood22@gmail.com

Corresponding authors.
a Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
c Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
d Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran
e Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (6)
Table 1. Demographic information of patients with COVID-19.
Table 2. Clinical features of patients with COVID-19.
Table 3. Vital signs of patients with COVID-19.
Table 4. Underlying diseases of patients with COVID-19.
Table 5. Laboratory findings of patients with COVID-19.
Table 6. Radiologic findings of patients with COVID-19.
Show moreShow less
Special issue
This article is part of special issue:
Vol. 23. Issue S2

COVID 19 & vaccines: Development and practice

More info
Abstract
Background

Coronavirus disease 19 (COVID-19) is a recently described infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Iran was the first country where the SARS-Cov-2 was detected in the Middle East. In the current study, we aimed to evaluate the clinical, radiological and laboratory findings in hospitalized COVID-19 confirmed cases in Iran.

Methods

The clinical manifestations, radiological data, laboratory findings, and the underlying diseases of the patients with COVID-19 were obtained from electronic medical records. Next, this information was compared in discharged and dead patients.

Results

Overall, 4028 patients with COVID-19 including 3088 discharged, 778 dead, and 162 still hospitalized patients were enrolled in this study. The highest percentage of people who recovered (55%) was between 30 and 60 years old and the highest percentage of deaths (74.4%) was more than 60 years old. Based on demographic data, 50.05% were female and 49.95% were male. Clinical evaluations revealed that dyspnea (56.9%), cough (31.4%) and fever (17.8%) were the most manifestations. Comorbidities were significantly higher in the dead group. Laboratory analysis revealed abnormalities in lymphocyte count (LYM), erythrocyte sedimentation rate (ESR), and inflammatory biomarkers such as C-reactive protein (CRP). The most prevalent computed tomography (CT) scan data were ground-glass opacity (GGO) (30.5%) and consolidation (9.4%).

Conclusions

Laboratory parameters and clinical and radiological findings help to evaluate the follow-up of the disease in patients. Age and comorbidities are factors that predispose people to COVID-19. Further research is needed to evaluate the effects of various factors on the progression of COVID-19 infection.

Keywords:
COVID-19
Iran
Clinical signs
SARS-CoV-2
Laboratory findings
Resumen
Antecedentes

La enfermedad por coronavirus de 19 (COVID-19) es una enfermedad infecciosa recientemente descrita causada por el síndrome respiratorio agudo severo por coronavirus 2 (SARS-CoV-2). Irán fue el primer país de Oriente Medio donde se detectó SARS-Cov-2. En el estudio actual, nuestro objetivo fue evaluar los hallazgos clínicos, radiológicos y de laboratorio en pacientes hospitalizados con confirmación de COVID-19 en Irán.

Métodos

Se obtuvieron las manifestaciones clínicas, los datos radiológicos, los hallazgos de laboratorio y las enfermedades subyacentes de los registros clínicos electrónicos. Seguidamente, se comparó esta información con los pacientes dados de alta y fallecidos.

Resultados

A nivel global, se incluyó en este estudio a 4.028 pacientes con COVID-19, de los cuales 3.088 habían recibido el alta, 778 habían fallecido, y 162 seguían hospitalizados. El mayor porcentaje de recuperaciones (55%) se produjo entre las personas de 30 a 60 años, y el mayor porcentaje de muertes (74,4%) se dio en los mayores de 60 años. Sobre la base de los datos demográficos, el 50,05% fueron mujeres y el 49,95% varones. Las evaluaciones clínicas revelaron que la disnea (56,9%), la tos (31,4%) y la fiebre (17,8%) fueron las manifestaciones más prevalentes. Las comorbilidades fueron significativamente más elevadas en el grupo de fallecidos. Las analíticas revelaron anomalías en cuanto a recuento linfocitario, tasa de sedimentación eritrocitaria (ESR), y biomarcadores inflamatorios tales como proteína C reactiva (PCR). Los datos procedentes de la tomografía computarizada (TC) fueron opacidad en vidrio esmerilado (GGO) (30,5%) y consolidación (9,4%).

Conclusiones

Los parámetros de laboratorio y los hallazgos clínicos y radiológicos ayudan a evaluar el seguimiento de la enfermedad en los pacientes. La edad y las comorbilidades son factores que predisponen a las personas a la COVID-19. Es necesaria más investigación para evaluar los efectos de los diversos factores en la progresión de la infección por COVID-19.

Palabras clave:
COVID-19
Irán
Signos clínicos
SARS-CoV-2
Hallazgos de laboratorio

Article

These are the options to access the full texts of the publication Vacunas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Vacunas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos